Drug intelligence / Profile preview

tuftsin

Development stage
Unknown
Modality
Peptides
Administration
Intravenous, Intraperitoneal, Intranasal
01

Overview

Tuftsin is a **naturally occurring tetrapeptide** (Thr-Lys-Pro-Arg, abbreviate TKPR), derived from the Fc domain of human immunoglobulin G. It is an endogenous **immunomodulatory peptide** that **stimulates phagocytic activity** and enhances immune responses, particularly by activating macrophages, monocytes, and microglia through binding to neuropilin-1 (NRP1) receptors. Tuftsin induces anti-inflammatory profiles in these cells via the TGF-β signaling pathway, promoting increased macrophage proliferation, differentiation to the M1 phenotype, and production of anti-tumor cytokines such as TNF-α and nitric oxide. Tuftsin exerts **broad immunostimulatory effects**, including enhanced antigen processing and cellular cytotoxicity, and has been investigated for roles in cancer, infection (eg. SARS-CoV-2), and neuroinflammatory diseases like multiple sclerosis. It shows no significant toxicity in preclinical or early clinical studies. Its therapeutic application is constrained by a short half-life, leading to exploration of more stable analogs[1][2][3][4][5].

Other names
TKPRThr-Lys-Pro-Argimmunomodulatory tetrapeptide
02

Targets

NRP1 (Neuropilin-1)TGFBR1ACE2 (Angiotensin-converting enzyme 2)TGFBR (TGF-beta receptor)

Beyond the preview

Go deeper on tuftsin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tuftsin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call